A retrospective study analysing age related outcomes of First-Line Pembrolizumab in a real-world Non-Small-Cell Lung Cancer (NSCLC) Cohort
Latest Information Update: 03 Mar 2021
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Mar 2021 New trial record
- 31 Jan 2021 Primary endpoint has not been met. (median overall survival (mOS) among age-stratified groups), as per Results presented at the 2020 World Conference on Lung Cancer
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer